As Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that $EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy...
Price entry $60 - target price $ 66 stop loss $58
Despite the stock been above the average analysts target we remain bullish om the setup technically, there is also the chance of upgrades to follow.
P/E ratio 20.65
Short interest 14.62 % Quite High, but normal in the Pharma sector.
Company profile
Eagle Pharmaceuticals, Inc. engages in the...
===============
SHORT TERM PRICE TARGET $68 +15% UPSIDE
===============
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
